Recon: Pfizer, Lilly move to sell drugs direct to consumers; Bharat Biotech to launch oral cholera vaccine

• Centene eliminates brokers’ commissions for Medicare drug plans (STAT)
• A virus bodega, DNC takeaways, and free Covid tests (STAT)
• Pfizer and Lilly want to sell you drugs directly (STAT)
• Lilly launches Zepbound vials in move that could ease supply constraints (STAT) (Reuters)
• Pfizer launches new website for migraine, respiratory offerings (Reuters)
• Delaware top court will hear drugmakers' appeal to end Zantac lawsuits (Reuters)
• Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug (Reuters)

• WHO launches plan to stanch mpox transmission and says the virus can be stopped (STAT)
• To stop mpox from becoming the next pandemic, we must address global vaccine inequities (STAT) Duality Biologics, an ADC partner of BeiGene and BioNTech, files for Hong Kong IPO (Endpoints)
• Responsible Antimicrobial Manufacturing A Must For UK’s Subscription Model Applicants (Pink Sheet)
• Brazilian Medicines Regulator Consults On Regulatory Sandbox (Pink Sheet)
• New mpox strain is changing fast; African scientists are ‘working blind’ to respond (Reuters)
• India's Bharat Biotech to launch oral cholera vaccine amid global shortage (Reuters)

• A Galapagos investor signals impatience with its turnaround efforts (STAT)
• Elektrofi, a startup that helps drugmakers formulate biologics for easier delivery, is raising a $112M Series C (Endpoints)
• Invivyd says new Phase 3 data on Covid antibody support prophylactic use (Endpoints)
• RA Capital and Forbion set up new autoimmune biotech with bispecific from Korean startup (Endpoints)
• AstraZeneca pours $135M into boosting biologics capacity in Sweden (Endpoints)
• Once-promising cancer drugs appear to protect mice from Alzheimer’s (Endpoints)
• Overcoming The Challenges Of Developing Hearing Loss Therapies (Pink Sheet)
• Regeneron’s Linvoseltamab CRL Underlines Risks Of Third-Party Manufacturers (Pink Sheet)

• Continuous glucose monitoring for the masses is here. Are we ready for it? (STAT)
• To help migraine patients — and sell more medicines — major drugmakers turn to telehealth (STAT)
• Illumina wins FDA approval for test to identify treatable cancers (Endpoints)
• Insulet expands Omnipod 5 pump to people with Type 2 diabetes (MedTech Dive)
• Inari updates label of clot removal device linked to 6 deaths (MedTech Dive)
• Siemens Healthineers to grow PET imaging with purchase of Novartis assets (MedTech Dive)
• Dexcom prices first over-the-counter glucose monitor (MedTech Dive)
• Co-Founder of ‘Anti-CRO’ Talks Building Better Clinical Trials (MedTech Insight)
• Final Guidance Sets Date For Mandatory De Novo Electronic Submissions (MedTech Insight)
• PreciseDX Aims To ‘Enrich’ Standard Of Care For Breast Cancer Recurrence Prediction (MedTech Insight)

• Glucose monitors, mpox vaccine inequity and effects of LGBTQ+ restrictions (STAT)
• The importance of reducing the financial burden of participating in clinical trials (STAT)
• Facility Deficiencies Drive Rising CRL Rates For CDER Biologics (Pink Sheet)
• FDA seeks feedback on predetermined change control plans (MedTech Dive)